Patents by Inventor Odile Petitgenet

Odile Petitgenet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chemical derivatives and their application as antitelomerase agents
    Patent number: 7179816
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: September 30, 2004
    Date of Patent: February 20, 2007
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Jean-Francois Riou, Marcel Alasia, Thomas Caulfield, Gilles Doerflinger, Jean-Louis Mergny, Abdelazize Laoui, Odile Petitgenet, Emmanuelle Renou
  • Chemical derivatives and their application as antitelomerase agents
    Publication number: 20050070575
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: September 30, 2004
    Publication date: March 31, 2005
    Applicant: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Jean-Francois Riou, Marcel Alasia, Thomas Caulfield, Gilles Doerflinger, Jean-Louis Mergny, Abdelazize Laoui, Odile Petitgenet, Emmanuelle Renou
  • Chemical derivatives and their application as antitelomerase agents
    Patent number: 6858608
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: February 22, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Jean-François Riou, Marcel Alasia, Thomas Caulfield, Gilles Doerflinger, Jean-Louis Mergny, Abdelazize Laoui, Odile Petitgenet, Emmanuelle Renou
  • Oxindoles which are inhibitors of CDK-1 and their application in therapeutics
    Publication number: 20040110770
    Abstract: The present invention relates to a compound of formula (I): 1
    Type: Application
    Filed: August 20, 2003
    Publication date: June 10, 2004
    Applicant: AVENTIS PHARMA SA
    Inventors: Jean-Francois Riou, Michel Maratrat, Lucile Grondard, Fabienne Thompson, Odile Petitgenet, Patrick Mailliet, Jacques Lavayre
  • Chemical derivatives and their application as antitelomerase agent
    Publication number: 20040053966
    Abstract: The present invention relates to cancer therapy and to novel anticancer agent having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: September 10, 2003
    Publication date: March 18, 2004
    Applicant: Aventis Pharms S.A.
    Inventors: Patrick Mailliet, Jean-Francois Riou, Jean-Louis Mergny, Abdelazize Laoui, Francois Lavelle, Odile Petitgenet
  • Chemical derivatives and their application as antitelomerase agent
    Patent number: 6645964
    Abstract: The present invention relates to cancer therapy and to novel anticancer agent having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: November 11, 2003
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Jean-François Riou, Jean-Louis Mergny, Abdelazize Laoui, François Lavelle, Odile Petitgenet
  • Chemical derivatives and their application as antitelomerase agents
    Publication number: 20030078263
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: January 9, 2002
    Publication date: April 24, 2003
    Inventors: Patrick Mailliet, Jean-Francois Riou, Marcel Alasia, Thomas Caulfield, Gilles Doerflinger, Jean-Louis Mergny, Abdelazize Laoui, Odile Petitgenet, Emmanuelle Renou